Showing results (11-20 of 210) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|October 20, 2021
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignanciesFranziska Modemann, Christian Niederwieser, Katja Weisel, et al.
Cancers|August 12, 2022
COVID-19 and Adult Acute Leukemia: Our Knowledge in ProgressFranziska Modemann, Susanne Ghandili, Stefan Schmiedel, et al.
Expert Review of Anticancer Therapy|June 23, 2018
Maintenance and continuous therapy for multiple myelomaPaul G Richardson, Jacob Laubach, Sara Gandolfi, et al.
Blood Reviews|April 17, 2021
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment optionsKarthik Ramasamy, Francesca Gay, Katja Weisel, et al.
Academic Radiology|September 7, 2010
Response assessment in patients with multiple myeloma during antiangiogenic therapy using arterial spin labeling and diffusion-weighted imaging: a feasibility studyMichael Fenchel, Marina Konaktchieva, Katja Weisel, et al.
Leukemia & Lymphoma|June 28, 2021
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myelomaDavid Siegel, Katja Weisel, Anita Zahlten-Kumeli, et al.
Annals of Hematology|July 1, 2014
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatmentManola Zago, Katharina Oehrlein, Corinna Rendl, et al.
Skeletal Radiology|April 3, 2015
Improvement of diagnostic confidence for detection of multiple myeloma involvement of the ribs by a new CT software generating rib unfolded images: Comparison with 5- and 1-mm axial imagesGeorg Homann, Katja Weisel, Deedar Farhad Mustafa, et al.
Annals of Hematology|November 16, 2022
VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experienceSusanne Ghandili, Dzenefa Alihodzic, Christian Wiessner, et al.
Haematologica|December 30, 2006
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphomaJörg T Hartmann, Ines Meisinger, Stefan M Kröber, et al.
Pageof 21